Ramandeep Saini

Mr. Ramandeep Saini

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2025 in Organoids
Verified
Journal Article
Open access
PDF file
Ayush MadanAyush Madan
Ayush Madan
Ramandeep SainiRamandeep Saini
Ramandeep Saini
Nainci DhimanNainci Dhiman
Nainci Dhiman
SJShu-Hui Juan
Shu-Hui Juan
MSMANTOSH KUMAR SATAPATHY
MANTOSH KUMAR SATAPATHY
Organoid technology has emerged as a revolutionary tool in cancer research, offering physiologically accurate, three-dimensional models that preserve the histoarchitecture, genetic stability, and phenotypic complexity of primary tumors. These self-organizing structures, derived from adult stem cells, induced pluripotent stem cells, or patient tumor biopsies, recapitulate critical aspects of tumor heterogeneity, clonal evolution, and microenvironmental interactions. Organoids serve as powerful systems for modeling tumor progression, assessing drug sensitivity and resistance, and guiding precision oncology strategies. Recent innovations have extended organoid capabilities beyond static culture systems. Integration with microfluidic organoid-on-chip platforms, high-throughput CRISPR-based functional genomics, and AI-driven phenotypic analytics has enhanced mechanistic insight and translational relevance. Co-culture systems incorporating immune, stromal, and endothelial components now permit dynamic modeling of tumor–host interactions, immunotherapeutic responses, and metastatic behavior. Comparative analyses with conventional platforms, 2D monolayers, spheroids, and patient-derived xenografts emphasize the superior fidelity and clinical potential of organoids. Despite these advances, several challenges remain, such as protocol variability, incomplete recapitulation of systemic physiology, and limitations in scalability, standardization, and regulatory alignment. Addressing these gaps with unified workflows, synthetic matrices, vascularized and innervated co-cultures, and GMP-compliant manufacturing will be crucial for clinical integration. Proactive engagement with regulatory frameworks and ethical guidelines will be pivotal to ensuring safe, responsible, and equitable clinical translation. With the convergence of bioengineering, multi-omics, and computational modeling, organoids are poised to become indispensable tools in next-generation oncology, driving mechanistic discovery, predictive diagnostics, and personalized therapy optimization.

2 July 2026 in Organoids
Verified
Journal Article
Open access
PDF file
Ramandeep SainiRamandeep Saini
Ramandeep Saini
BTBishakha Thakur
Bishakha Thakur
BBBikram Kumar Basaba
Bikram Kumar Basaba
MSMANTOSH KUMAR SATAPATHY
MANTOSH KUMAR SATAPATHY
The convergence of artificial intelligence (AI) and organoid technology represents a transformative advance toward precision and predictive medicine. Organoids derived from pluripotent stem cells or patient tissues provide physiologically relevant three-dimensional models that recapitulate key aspects of native organ architecture and function. However, intrinsic biological heterogeneity, high-content imaging outputs, and dynamic spatiotemporal processes pose significant analytical challenges that exceed the capacity of conventional approaches. Recent advances in AI and machine learning enable automated image segmentation, quantitative morphometric profiling, and predictive modeling of organoid growth, differentiation, and therapeutic response, thereby enhancing reproducibility and translational relevance. The integration of multimodal datasets, including imaging, genomics, transcriptomics, epigenomics, proteomics, and metabolomics, has further enabled the development of organoid-based digital twins and in silico disease simulations to optimize personalized therapy. AI-enabled organoid-on-a-chip platforms, cloud-based analytics, and federated learning frameworks are accelerating the emergence of scalable, privacy-preserving, and data-driven biomedical ecosystems. Despite these advances, critical challenges persist, including data standardization, model interpretability, ethical governance, and clinical validation. In contrast to existing reviews that emphasize isolated AI applications, this study proposes a unified translational framework integrating AI-driven image analytics, multi-omics integration, digital twins, and organoid-on-a-chip systems within a precision medicine paradigm. By synthesizing current developments, methodological advances, and emerging trends, this study highlights how AI-powered organoid platforms can bridge experimental biology and clinical decision-making, with broad implications for drug discovery, disease modeling, and regenerative medicine. This review aims to provide a comprehensive overview of artificial intelligence–enabled organoid platforms by integrating advances in image analytics, multi-omics data integration, digital twins, and microphysiological systems, while highlighting their potential applications and future directions in precision medicine, drug discovery, and regenerative healthcare.

13 April 2026
Verified
Book Chapter
Closed access
PSPranshul Sethi
Pranshul Sethi
MBMegha Bahuguna
Megha Bahuguna
Ramandeep SainiRamandeep Saini
Ramandeep Saini
Sachchida Nand RaiSachchida Nand Rai
Sachchida Nand Rai
Ayush MadanAyush Madan
Ayush Madan

11 September 2026 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
Ramandeep SainiRamandeep Saini
Ramandeep Saini
MSMANTOSH KUMAR SATAPATHY
MANTOSH KUMAR SATAPATHY
Although significant progress has been made in nanotechnology, the clinical translation of central nervous system (CNS) therapeutics has been limited. While engineered nanocarriers have greatly enhanced blood–brain barrier (BBB) transport, there is now growing evidence that enhanced brain delivery is not sufficient for therapeutic success. Based on this, it is suggested that the key obstacle to translation is now the poor engagement of the molecule at the BBB, its intracellular pharmacology, and its pharmacodynamic response. This perspective underscores the evolving paradigm shift from delivery-based nanomedicine to target-based precision pharmacology where therapeutic engagement is quantified by target occupancy, pathway modulation in the context of disease, and translational relevance to the human condition. This integration of validated disease biology and intelligent delivery design can now be achieved through the advent of new technologies such as artificial intelligence (AI), systems pharmacology, receptor-guided engineering of nanocarriers, spatial multi-omics, brain organoids, and BBB-on-chip technologies. This target-oriented approach is expected to facilitate clinical reproducibility and accelerate the development of safer, more effective, and individualized nanotherapeutics for CNS diseases.

12 October 2026 in Bacteria
Verified
Journal Article
Open access
PDF file
Ramandeep SainiRamandeep Saini
Ramandeep Saini
BTBishakha Thakur
Bishakha Thakur
Ayush MadanAyush Madan
Ayush Madan
MSMANTOSH KUMAR SATAPATHY
MANTOSH KUMAR SATAPATHY
Microbial biofilms are highly structured multicellular communities that exhibit remarkable tolerance to antimicrobial agents and host defenses, contributing to persistent infections, industrial biofouling, food contamination, and environmental challenges. Conventional microbiological approaches have greatly advanced our understanding of biofilm formation but remain insufficient to resolve the spatial, molecular, and functional heterogeneity that underpins biofilm resilience. This review discusses how recent advances in high-resolution imaging, multi-omics technologies, single-cell and spatially resolved analyses, and artificial intelligence (AI) are transforming biofilm research from descriptive observation to precision microbiology. We critically examine state-of-the-art analytical platforms, including confocal and super-resolution microscopy, electron microscopy, Raman-based imaging, genomics, transcriptomics, proteomics, metabolomics, and emerging spatial multi-omics approaches, highlighting their complementary roles in deciphering biofilm architecture, regulatory networks, and metabolic specialization. AI/ML approaches are increasingly being applied to image analysis, multimodal data integration, predictive modeling, biomarker identification, and systems-level interpretation of biofilm biology. Furthermore, we discuss how these technological advances are enabling mechanism-based precision antibiofilm strategies, including extracellular polymeric substance-targeting enzymes, quorum-sensing inhibitors, nanotechnology-enabled therapeutics, bacteriophage-based interventions, and synthetic biology approaches. We highlight the major translational challenges, including data standardization, explainable AI, multimodal integration, benchmark datasets, and clinical validation, and outline future directions for developing clinically relevant, data-driven antibiofilm therapies. This review provides an integrated framework connecting advanced analytical technologies with next-generation precision antibiofilm interventions and offers perspectives for accelerating their translation into clinical and industrial applications.